Physician profile
Paul S Modlinger
NPI 1053405688
$17,915.99
in general payments reported to CMS, 2019-2025
25 companies · $960 in 2025
The $960 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,615 · 2020: $3,679 · 2021: $323 · 2022: $1,558 · 2023: $5,294 · 2024: $488 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,375 · Food and Beverage: $2,413 · Travel and Lodging: $828 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,375.00 |
| Food and Beverage | $2,413.12 |
| Travel and Lodging | $828.47 |
| Education | $124.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $8,207.24 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $6,362.96 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $879.62 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $301.30 | 2019-2023 | Farxiga |
| Mallinckrodt Enterprises LLC | $236.77 | 2019 | |
| Amgen INC. | $181.53 | 2019-2025 | Uplizna |
| Recor Medical INC | $178.90 | 2025 | Paradise Ultrasound Renal Denervation System |
| Vifor Pharma, INC. | $178.81 | 2021-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $176.29 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $145.96 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $143.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $138.60 | 2019 | |
| Akebia Therapeutics INC | $107.21 | 2019-2024 | Vafseo |
| Ardelyx, INC. | $103.13 | 2025 | Xphozah 30 Mg |
| Genzyme Corporation | $103.04 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $98.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.73 | 2019 | |
| Aurinia Pharma U.S., INC. | $97.26 | 2023 | Lupkynis |
| Novo Nordisk INC | $44.35 | 2025 | Rybelsus, Ozempic, Wegovy |
| Travere Therapeutics, INC. | $39.44 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $32.96 | 2019-2021 | |
| Medtronic, INC. | $17.28 | 2023 | Ellipsys Vascular Access System |
| Calliditas Therapeutics US INC. | $16.75 | 2022 | |
| Daiichi Sankyo INC. | $14.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Modlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.